ArticleAntimicrobial agents and chemotherapy2020
First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Chemoproteomic Elucidation of β-Lactam Drug Targets inACS infectious diseases · 2026Article
- Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens forAntimicrobial agents and chemotherapy · 2026Article
- Synergistic activity of dual β-lactams againstMicrobiology spectrum · 2026Article
- In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates.The Journal of antimicrobial chemotherapy · 2026Article
- A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference inACS infectious diseases · 2025Article
- Oral β-lactam combinations are effectiveMicrobiology spectrum · 2025Article
- Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect againstMicrobiology spectrum · 2025Article
- Repression of mab_1999 impairs growth and alters cellular morphology of Mycobacterium abscessus.BMC microbiology · 2025Article
- Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens forbioRxiv : the preprint server for biology · 2025Article
- Novel C5α-substituted carbapenems enhanceAntimicrobial agents and chemotherapy · 2025Article
- In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection ofAntibiotics (Basel, Switzerland) · 2025Article
- Durlobactam in combination with β-lactams to combatAntimicrobial agents and chemotherapy · 2025Article
- Durlobactam to boost the clinical utility of standard of care β-lactams againstAntimicrobial agents and chemotherapy · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
- Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare.The Journal of antimicrobial chemotherapy · 2024Review
- Structure of MltG from Mycobacterium abscessus reveals structural plasticity between composed domains.IUCrJ · 2024Article
- Article
- Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors inAntimicrobial agents and chemotherapy · 2024Article
- Predominantly Orphan Secretome in the Lung PathogenMicroorganisms · 2024Article
- Drug Discovery in the Field of β-Lactams: An Academic Perspective.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Alaa R M SayedDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Nirav R ShahDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Kari B BassoDepartment of Chemistry, University of Florida, Gainesville, Florida, USA.
Manasi KamatDepartment of Chemistry, University of Florida, Gainesville, Florida, USA.
Yuanyuan JiaoDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Bartolome MoyaServicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears, Palma de Mallorca, Spain.
Dhruvitkumar S SutariaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Yinzhi LangDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Xun TaoDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Weiguo LiuInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
Eunjeong ShinDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Jieqiang ZhouDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Carolin WerkmanDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Arnold LouieInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
George L DrusanoInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.ORCID 0000-0001-9162-7332
Jürgen B BulittaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA jbulitta@cop.ufl.edu.ORCID 0000-0001-7352-3097
Funding
Combating resistant superbugs by understanding the molecular determinants of target site penetration and bindingR01AI136803 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$5.7MNovel Strategies for Antibiotic Combinations to Combat Gram-negative SuperbugsR01AI148560 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BULITTA, JURGEN BERND, TSUJI, BRIAN · 2020 to 2024
$3.9MNext-generation combination dosing strategies to combat resistant Acinetobacter baumanniiR01AI130185 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$3.4MAcquisition of a Q Exactive HF Hybrid Quadrupole-OrbitrapS10OD021758 · OD · UNIVERSITY OF FLORIDA · PI BASSO, KARI B · 2017 to 2017
$600kNIAID NIH HHS R01 AI130185NIAID NIH HHS R01 AI136803NIAID NIH HHS R01 AI148560NIH HHS S10 OD021758
Abstract
PubMed holds no abstract for this paper.
Indexed as
beta-Lactamase InhibitorsMycobacterium abscessusAnti-Bacterial Agentsbeta-LactamsMicrobial Sensitivity TestsPenicillin-Binding ProteinsPenicillinsAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamsPenicillin-Binding ProteinsPenicillinsbeta-lactamscell wall biosynthesisdrug-resistant bacteriaMycobacterium abscessusPbpApenicillin-binding proteinsPonA1PonA2principal component analysisreceptor binding
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.